AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01900730 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pill Diary
Description: Patient given a pill diary to record the time each dose taken.
Study NCT01900730 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Drainage Diary
Description: Patient completes daily diary of drainage with the date and amount of fluid drained each day at home. Drained fluid from the day before brought to each clinic visit to give to the research team.
Study NCT01900730 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Drainage Diary
Description: Patient completes daily diary of drainage with the date and amount of fluid drained each day at home. Drained fluid from the day before brought to each clinic visit to give to the research team.
Study NCT03985670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teripalimab plus chemotherapy
Description: teripalimab 240mg d1 paclitaxel 150mg/m2 d1 cisplatin 70mg/m2 d1
Study NCT03985670 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy plus teripalimab
Description: paclitaxel 150mg/m2 d1 cisplatin 70mg/m2 d1 teripalimab 240mg d3
Study NCT02222155 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CCX168 10 mg, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids
Study NCT02222155 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CCX168 30 mg, twice daily, cyclophosphamide/rituximab plus glucocorticoids
Study NCT02222155 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids
Study NCT03202914 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual protein and phosphorus diet
Description: Diet intervention
Study NCT03202914 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low protein and phosphorus diet
Description: Diet intervention
Study NCT03202914 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Very low protein and phosphorus
Description: Diet intervention
Study NCT01627457 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Guided Exercise (GEx) system
Description: 30 CAD patients will wear the GEx system while they are trained during inpatient cardiac rehabilitation (phase II) in order to evaluate accuracy and safety of data like heart rate, breathing, ECG three times a week for about three weeks. In a second step these patients train at home (phase III) in order to evaluate practicability and technical problems of the GEx device three times a week for about three weeks.
Study NCT02201225 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional supplement with micronutrient
Description: Nutritional supplement powder with micronutrients packed as 27 g individual sachet, administered orally as a single serve
Study NCT02201225 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Nutritional supplement without micronutrient
Description: Nutritional supplement powder without micronutrients packed as 27 g individual sachet, administered orally as a single serve
Study NCT01374919 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ferumoxytol
Description: IV administration of 1020 mg of ferumoxytol in 15 minutes
Study NCT03006445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FYU-981
Study NCT02243930 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Disposable distal attachment
Study NCT02445456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sienna+ injection
Description: Endoscopic injection of magnetic tracer
Study NCT02445456 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI scan
Description: MRI scan of pelvis to detect spread of magnetic tracer
Study NCT02445456 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery to excise rectal cancer
Description: Surgery as scheduled according to size and stage of rectal cancer. This will be either radical surgery or transanal endoscopic microsurgery (TEM)
Study NCT02445456 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sentimag probe
Description: Probe to detect the previously injected magnetic tracer (Sienna+)
Study NCT01440283 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy (IMRT)
Description: IMRT delivery will follow current conventional volume-targeting guidelines, however, appropriate application within the abdomen will be determined by ascertaining intra-abdominal organ motion and the potential for reducing normal tissue dose, while simultaneously increasing dose delivered to target tissues, particularly when dose escalation for gross residual disease is required. Concurrent neuro-hormonal tests, cytokine analyses, functional and morphologic imaging will generate novel data describing the acute and chronic effects of radiotherapy within the abdomen.
Study NCT03151278 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Zero-fluoroscopy ablation
Description: Catheter ablation will be performed under the guidance of one kind of three-dimensional navigation system and without fluoroscopic guidance.
Study NCT03151278 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional fluoroscopy ablation
Description: Catheter ablation will be performed using fluoroscopy plus one kind of three-dimensional navigation system.
Study NCT02458482 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AccuPAP
Description: The AccuPAP device used by participants will give 2.5mg and 0.5mg nebulized Albuterol and Ipratropium over 5 minutes. Inspiratory and expiratory pressures to be set at 6 and 12 cm H20 respectively. This therapy is repeated at 20 and 40 minutes for a total of three AccuPAP treatments.
Study NCT02458482 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol and Ipratropium Continuous Nebulizer
Description: 10mg Albuterol and 1.5mg Ipratropium continuous nebulizer treatment will be administered to a Control group over a one hour period.
Study NCT03180606 — intervention group
Intervention type: OTHER
Intervention: Multi-disciplinary and personalized primary care
Description: Team-based primary care where nurse, GP, social-worker, physiotherapist, occupational therapist evaluate and give treatment
Study NCT02917902 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Food boxes
Description: Box of approximately 50 pounds of nutritious foods provided by food pantry, including fresh fruits and vegetables as well as shelf-stable items selected for diabetic patients, along with brief education provided by food pantry staff.
Study NCT02917902 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food boxes
Description: Box of approximately 50 pounds of nutritious foods provided by food pantry, including fresh fruits and vegetables as well as shelf-stable items selected for diabetic patients, along with brief education provided by food pantry staff.
Study NCT02962297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E softgel
Description: All participants receive standardized recommendations for life-style modification (Diet modification, weight loss, exercise).
Study NCT02962297 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All participants receive standardized recommendations for life-style modification (Diet modification, weight loss, exercise).~Height and weight, waist-to-hip ratio Review of diet and exercise
Study NCT01924078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: metronomic use: capecitabine 500mg/tid
Study NCT01924078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aromatase Inhibitors (AIs)
Description: Anastrozole 1mg/day p.o,Exemestane 25mg/day,Letrozole 2.5mg/day p.o.
Study NCT03627585 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Personalised programming
Description: Reprogramming protocol already test in an observation cohort will be utilised which will direct physiologists to consider pacemaker mode, base rate, utilisation of rate response, hysteresis, sleep and rest rates as well as lead outputs.
Study NCT01541150 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: neuropsychological questionnaires
Description: Due to this study population (inmates), the investigators have decided to classify the protocol as and interventionnal study.
Study NCT01541150 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: neuropsychological questionnaires
Description: Due to this study population (inmates), the investigators have decided to classify the protocol as and interventionnal study.
Study NCT02007122 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ceftaroline in CRRT
Description: Plasma levels of ceftaroline will be measured in patients receiving CRRT
Study NCT02007122 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ceftaroline in IRRT
Description: Ceftaroline plasma levels will be measured in patients receiving intermittent renal replacement therapy
Study NCT00590408 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: coenzyme Q10
Description: 60mg capsule twice daily for 12 weeks
Study NCT00590408 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: matching placebo
Description: matching placebo capsule twice daily for 12 weeks
Study NCT01167309 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LEO 27847
Description: First in patient
Study NCT01167309 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LEO 27847
Description: First in patient
Study NCT04117841 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: All groups will undergo observational data collection. No interventions will be made to patient care.
Study NCT03435705 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: maintaining of occupational therapy
Description: 8 home sessions over a 4 months period with caregivers' education, occupational therapy and care coordination for post intervention
Study NCT00086762 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MR Therapy
Description: Arm I: Participants receive Mindfulness Relaxation (MR) therapy as in the pilot phase. Instructions given on breathing techniques and other practices to help relax mind and body.
Study NCT00086762 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxing Music (RM) Therapy
Description: Participants listen to relaxing music (with no instructions on relaxation techniques) for 30 minutes before and during each chemotherapy session AND at least once daily for the entire duration of chemotherapy treatment
Study NCT00086762 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Symptom Management
Description: Participants receive standard symptom management education. General information received about how to manage symptoms that develop due to the chemotherapy.
Study NCT00086762 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaire completion at baseline, during the middle of chemotherapy treatment, and at chemotherapy completion.
Study NCT00086762 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: Questionnaire completion at baseline, during the middle of chemotherapy treatment, and at chemotherapy completion.
Study NCT01702584 — intervention group
Intervention type: PROCEDURE
Intervention: stent assisted embolization
Description: stent assisted embolization and anti-thrombotic management
Study NCT03252353 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: octreotide capsules
Description: octreotide capsules 40 mg/day, 60 mg/day, 80 mg/day (individual dose titration)
Study NCT03252353 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Matching placebo capsules
Study NCT04520386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMT-111
Description: Pre-filled Syringe
Study NCT01740219 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Capacity Enhancement
Description: Churches in the Capacity Enhancement intervention will be invited to work with CRUZA staff over the course of a three month intervention to implement health promotion activities in their church and participate in capacity-building educational workshops. Participants may also receive technical assistance from Health Educators in order to implement their cancer education activities.
Study NCT01740219 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Dissemination
Description: Churches in the Standard Dissemination arm will receive program materials with information about cancer prevention/early detection and health resources.
Study NCT01809171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: ampoule
Study NCT01809171 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: ampoule
Study NCT04191057 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Free light chains
Description: Blood samples will be collected and analyzed
Study NCT02417636 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Task Shifting
Description: Participants will be screened for eligibility for ART and the study and then enrolled initiated on ART by a Nursing Officers and then followed and monitored for ART adherence on a monthly basis for 12months. Quarterly, sexual behavior and quality of life questionnaires will be administered. CBC, CD4, HIV-1 Viral load, renal and liver function test will be done biannually. Nursing Officers will be free to consult with clinicians on the management of patients.
Study NCT02417636 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Task Shifting
Description: Participants will be screened for eligibility for ART and the study and then enrolled initiated on ART by a Nursing Officers and then followed and monitored for ART adherence on a monthly basis for 12months. Quarterly, sexual behavior and quality of life questionnaires will be administered. CBC, CD4, HIV-1 Viral load, renal and liver function test will be done biannually. Nursing Officers will be free to consult with clinicians on the management of patients.
Study NCT00323193 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOVE!
Description: group based psychoeducation, motivation and support
Study NCT03467165 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRgFUS treatment
Description: MRgFUS treatment of pain caused by trapeziometacarpal OA (and/or scaphotrapezial OA)
Study NCT03467165 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRgFUS treatment
Description: MRgFUS treatment of pain caused by hip OA
Study NCT00980538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etravirine
Description: Participants will be dosed with etravirine by weight up to a maximum dose of 200 mg bid until switched to an etravirine-based treatment regimens (i.e. commercially available and reimbursed, or accessible through another source) or local standard of care, as appropriate.
Study NCT01089699 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: online support group
Description: online support group
Study NCT01089699 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: home study support materials
Description: self-study materials
Study NCT04456478 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pH at 7.38 ± 0.02
Description: In the 3 centers of the study, IVF-ICSI will be performed according to the usual procedure: ovarian stimulation, oocyte retrieval, sperm microinjection by ICSI, embryo culture in Global® Total HSA medium, embryo selection and transfer at day 3. The day of the oocyte puncture, the embryologist will proceed to the 1: 1 randomization: culture of the embryos in a medium with a pH at 7.38 ± 0.02. We have chosen to study specifically the early stages of fertilization and embryo development (until day 3), stages for which extracellular pH control is more critical because the intracellular pH regulatory mechanisms are somewhat limited and could be exceeded.
Study NCT04456478 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pH at 7.22 ± 0.02
Description: In the 3 centers of the study, IVF-ICSI will be performed according to the usual procedure: ovarian stimulation, oocyte retrieval, sperm microinjection by ICSI, embryo culture in Global® Total HSA medium, embryo selection and transfer at day 3. The day of the oocyte puncture, the embryologist will proceed to the 1: 1 randomization: culture of the embryos in a medium with a pH at 7.22 ± 0.02. We have chosen to study specifically the early stages of fertilization and embryo development (until day 3), stages for which extracellular pH control is more critical because the intracellular pH regulatory mechanisms are somewhat limited and could be exceeded.
Study NCT01548677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: 8 mg/kg of loading dose IV over 90 minutes for the first cycle, followed by 6 mg/kg IV over 60 minutes every 3 weeks for the 5 subsequent cycles.
Study NCT01581970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Patients will be given oral cyclophosphamide 50 mg twice daily to be self-administered starting the first day of therapy with weekly cetuximab for 12 weeks or until disease progression.
Study NCT01581970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: The initial dose of cetuximab 400 mg/m\^2 is administered over 120 minutes followed by weekly infusions of cetuximab 250 mg/m\^2 intravenously (IV) over 60 minutes.
Study NCT04296149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Y90-DOTA-Tyr3-Octreotide
Description: Patients enrolled for surgery will receive a small amount of Y-90-DOTATOC, in order to check beta- radioactivity by the probe
Study NCT02045927 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: sedation monitoring with RASS score
Study NCT02045927 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sedation monitoring with RASS score
Study NCT02045927 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sedation monitoring with BIS-Guided monitoring
Study NCT01826123 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional laboratory testing (Central laboratory)
Description: aPTT, INR, fibrinogen concentration, platelet count
Study NCT01826123 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: POC testing
Description: ROTEM: Clotting time (CT) in the EXTEM- and INTEM-test, Maximal clot firmness in the FIBTEM-test, Clot Lysis Index (CLI) multiplate: Area under the aggregation curve following stimulation with arachidonic acid (ASA) and Adenosine diphosphate (ADP)
Study NCT01521988 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Atrial flutter ablation
Description: Radiofrequency ablation of Atrial flutter
Study NCT01521988 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Atrial flutter ablation and pulmonary vein isolation
Description: Radiofrequency ablation of atrial flutter and pulmonary vein isolation using cryoablation
Study NCT04548440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Route of administration: Intravenous
Study NCT04548440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Route of administration: Intravenously over 30min
Study NCT04548440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Route of administration: Intravenous
Study NCT00970697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: becaplermin gel
Description: the amount of the gel to be applied was determined based on ulcer area at inclusion and remains identical during all the treatment The posology was identical to what is recommended for Regranex gel®: a single 15g-tube is enough to treat a 5 cm2-wound during 6 weeks (1 cm of gel is applied daily for 5 cm2) Wound was then recovered by a moist saline gauze and a bandage. Becaplermin gel is packaged into masked 15g-tubes.
Study NCT00970697 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duoderm Hydrogel™
Description: The amount of the gel to be applied was determined based on ulcer area at inclusion, and remains identical during all the treatment. The posology was identical to what is recommended for Regranex gel®: a single 15g-tube is enough to treat a 5 cm2-wound during 6 weeks (1 cm of gel is applied daily for 5 cm2) Wound was then recovered by a moist saline gauze and a bandage. Hydrogel dressing is identical in appearance, color, consistency, and odor than becaplermin gel, and packaged in similar masked15g-tubes.
Study NCT01575223 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NeilMed sinus rinse
Description: High volume saline irrigation
Study NCT01575223 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Salinex
Description: Low volume saline irrigation
Study NCT01038791 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: heated humidification
Description: temperature 35°
Study NCT01038791 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: heat and moisture exchanger
Description: single patient device
Study NCT01038791 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: usual mechanical ventilation without humidification
Description: mechanical ventilation with usual parameters
Study NCT00411203 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen Citrate
Study NCT00411203 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo